{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T21:04:15Z","timestamp":1722891855319},"reference-count":39,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,9,19]],"date-time":"2002-09-19T00:00:00Z","timestamp":1032393600000},"content-version":"vor","delay-in-days":80,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2002,7]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold> The aim of the study was to determine the effectiveness and toxicity of cladribine (2\u2010CdA) used alone or in combination with prednisone (P) or cyclophosphamide and mitoxantrone in re\u2010treatment of patients with progressive B\u2010cell chronic lymphocytic leukemia (B\u2010CLL). We analyzed treatment outcome in 40 patients who had responded to previous treatment with 2\u2010CdA\u2010based regimens. Criteria for re\u2010treatment were the same as for the first treatment. The patients were retreated with the same agents if they responded to the first treatment and then relapsed with progressive disease not earlier than 3 months after achieving the first response. Eight patients received 2\u2010CdA alone (0.12\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>\u2003d<jats:sup>\u22121<\/jats:sup>) i.v. for 5\u2003d, and 21 patients additionally were given P (30\u2003mg\u2003m<jats:sup>\u22122<\/jats:sup>\u2003d<jats:sup>\u22121<\/jats:sup>) orally, also for 5\u2003d. Eleven patients received 2\u2010CdA for 3\u2003d combined with cyclophosphamide (650\u2003mg\u2003m<jats:sup>\u22122<\/jats:sup>) i.v. and mitoxantrone (10\u2003mg\u2003m<jats:sup>\u22122<\/jats:sup>) i.v. on day 1 (CMC regimen). The cycles were repeated usually at 4\u2003wk intervals or longer if severe myelosuppression or infections occurred. The therapy was finished if complete remission (CR) was achieved or until maximum of six courses. Overall response (OR) in re\u2010treatment was obtained in 16 out of 40 (40%) patients (95% CI 16\u201364), including 62% after 2\u2010CdA, 33% after 2\u2010CdA\u2003+P and 36% after CMC. CR was obtained in four (10%) patients. Residual disease evaluated in the patients with CR by surface immunophenotyping had been demonstrated in 5 out of 16 (31%) patients after the first treatment and in one out of four (25%) patients after re\u2010treatment. The median progression\u2010free survival (PFS) was 16 months (range 3\u201339) for the first treatment and 9.5 months (range 3\u201318) for re\u2010treatment (<jats:italic>P<\/jats:italic>=0.34). Grade III or IV neutropenia was observed in 20% patients during the first treatment and in 35% patients during re\u2010treatment (<jats:italic>P<\/jats:italic>=0.1). 2\u2010CdA\u2010induced thrombocytopenia occurred in 20% and 42% of the patients, respectively (<jats:italic>P<\/jats:italic>=0.05). Anemia was also more frequent during re\u2010treatment (35%) than during the first treatment (7%) (<jats:italic>P<\/jats:italic>=0.007). Autoimmune hemolytic anemia developed in four (10%) of the patients during or after re\u2010treatment. Severe infections, including pneumonia and herpes reactivation, occurred in 11 patients during the first treatment and in 10 patients during re\u2010treatment. Twelve (30%) patients died during the study. Infections were the cause of death in six and AIHA in two patients. In conclusion, 2\u2010CdA applied in monotherapy or in combination with prednisone or cyclophosphamide and mitoxantrone has therapeutic activity in some B\u2010CLL patients in whom these drugs induced earlier complete or partial remission. However, since the second response is usually shorter and myelotoxicity more pronounced than during the first therapy, more clinical trials to find other therapeutical approaches are necessary.<\/jats:p>","DOI":"10.1034\/j.1600-0609.2002.02711.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T18:53:10Z","timestamp":1047408790000},"page":"27-36","source":"Crossref","is-referenced-by-count":10,"title":["Re\u2010treatment with cladribine\u2010based regimens in relapsed patients with B\u2010cell chronic lymphocytic leukemia"],"prefix":"10.1111","volume":"69","author":[{"given":"Tadeusz","family":"Robak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy Z.","family":"Bo\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Kasznicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"G\u00f3ra\u2010Tybor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lech","family":"Konopka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Dmoszy\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadwiga","family":"Dwilewicz\u2010Trojaczek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dariusz","family":"Wo\u0142owiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Polish Leukemia Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,9,19]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_6_2_2","DOI":"10.1182\/blood.V86.7.2463.2463"},{"key":"e_1_2_6_3_2","first-page":"1005","article-title":"Fludarabine. An update of its pharmacology and use in the treatment of haematologic malignancies","volume":"53","author":"Adkins JC","year":"1997","journal-title":"Drugs"},{"doi-asserted-by":"publisher","key":"e_1_2_6_4_2","DOI":"10.1080\/10428190290012029"},{"doi-asserted-by":"publisher","key":"e_1_2_6_5_2","DOI":"10.1182\/blood.V81.11.2878.2878"},{"doi-asserted-by":"publisher","key":"e_1_2_6_6_2","DOI":"10.1182\/blood.V92.4.1165"},{"doi-asserted-by":"publisher","key":"e_1_2_6_7_2","DOI":"10.1200\/JCO.1996.14.7.2160"},{"doi-asserted-by":"publisher","key":"e_1_2_6_8_2","DOI":"10.1046\/j.1365-2141.2000.01850.x"},{"doi-asserted-by":"publisher","key":"e_1_2_6_9_2","DOI":"10.1093\/oxfordjournals.annonc.a010604"},{"doi-asserted-by":"publisher","key":"e_1_2_6_10_2","DOI":"10.3109\/10428190109060345"},{"doi-asserted-by":"publisher","key":"e_1_2_6_11_2","DOI":"10.1056\/NEJM200012143432402"},{"key":"e_1_2_6_12_2","first-page":"2723","article-title":"Cladribine with prednisone versus chlorambucil with prednisone as first\u2010line therapy in chronic lymphocytic leukemia: Report of a prospective, randomized, multicenter trial","volume":"96","author":"Robak T","year":"2000","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_6_13_2","DOI":"10.1016\/S0140-6736(96)91681-5"},{"doi-asserted-by":"publisher","key":"e_1_2_6_14_2","DOI":"10.1182\/blood.V98.8.2319"},{"key":"e_1_2_6_15_2","first-page":"92","article-title":"Retreatment with fludarabine: outcome in 203 patients with relapsed or refractory CLL treated with salvage therapy","volume":"42","author":"Thomas DA","year":"2000","journal-title":"Hematol Cell Ther"},{"doi-asserted-by":"publisher","key":"e_1_2_6_16_2","DOI":"10.3109\/10428199409051654"},{"doi-asserted-by":"publisher","key":"e_1_2_6_17_2","DOI":"10.1002\/ajh.2830290307"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute sponsored working group guidelines for chronic lymphocytic leukemia. Revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson BD","year":"1996","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_6_19_2","DOI":"10.1038\/sj.leu.2402216"},{"doi-asserted-by":"publisher","key":"e_1_2_6_20_2","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"e_1_2_6_21_2","first-page":"253","volume-title":"Chronic Lymphocytic Leukemia. Recent Progress and Future Direction","author":"Rai KR","year":"1987"},{"doi-asserted-by":"publisher","key":"e_1_2_6_22_2","DOI":"10.1046\/j.1365-2141.1997.9922637.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V80.1.29.29","article-title":"Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic and molecular analysis","volume":"80","author":"Robertson LE","year":"1992","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_6_24_2","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"doi-asserted-by":"publisher","key":"e_1_2_6_25_2","DOI":"10.2307\/2531951"},{"doi-asserted-by":"publisher","key":"e_1_2_6_26_2","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_27_2","first-page":"5956","article-title":"Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line","volume":"59","author":"Mansson E","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_6_28_2","first-page":"3559","article-title":"Resistance to 2\u2010chloro\u20102\u2032\u2010deoxyadenosine of the human B\u2010cell leukemia cell line EHEB","volume":"7","author":"Cardoen S","year":"2001","journal-title":"Clin Cancer Res"},{"doi-asserted-by":"publisher","key":"e_1_2_6_29_2","DOI":"10.1182\/blood.V99.2.655"},{"doi-asserted-by":"publisher","key":"e_1_2_6_30_2","DOI":"10.1200\/JCO.2001.19.5.1414"},{"doi-asserted-by":"publisher","key":"e_1_2_6_31_2","DOI":"10.1046\/j.1365-2141.2001.02959.x"},{"doi-asserted-by":"publisher","key":"e_1_2_6_32_2","DOI":"10.1111\/j.1365-2141.1995.tb05300.x"},{"doi-asserted-by":"publisher","key":"e_1_2_6_33_2","DOI":"10.1111\/j.1600-0609.1997.tb00933.x"},{"doi-asserted-by":"publisher","key":"e_1_2_6_34_2","DOI":"10.3109\/10428199809068575"},{"doi-asserted-by":"publisher","key":"e_1_2_6_35_2","DOI":"10.1002\/ajh.2830480423"},{"key":"e_1_2_6_36_2","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1182\/blood.V95.9.2786.009k30_2786_2792","article-title":"Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic and prognostic features","volume":"95","author":"Mauro FR","year":"2000","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_6_37_2","DOI":"10.1038\/sj.leu.2400816"},{"doi-asserted-by":"publisher","key":"e_1_2_6_38_2","DOI":"10.1182\/blood.V96.1.71"},{"key":"e_1_2_6_39_2","first-page":"S38","article-title":"Prophylactic strategies to meet infectious complications in fludarabine treated CLL","volume":"11","author":"Sudhoff T","year":"1997","journal-title":"Leukemia"},{"doi-asserted-by":"publisher","key":"e_1_2_6_40_2","DOI":"10.1002\/ajh.2830490207"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2002.02711.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2002.02711.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2002.02711.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T22:43:04Z","timestamp":1697496184000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2002.02711.x"}},"subtitle":["Efficacy and toxicity in comparison with previous treatment"],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["10.1034\/j.1600-0609.2002.02711.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2002.02711.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}